Comparative Pharmacology
Head-to-head clinical analysis: LEVEMIR versus LEVEMIR INNOLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVEMIR versus LEVEMIR INNOLET.
LEVEMIR vs LEVEMIR INNOLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin detemir is a long-acting basal insulin analogue. It binds to insulin receptors, activating downstream signaling pathways that promote glucose uptake in muscle and adipose tissue, inhibit hepatic gluconeogenesis, and suppress lipolysis and proteolysis. The myristic acid side chain enables reversible binding to albumin, resulting in slow and predictable absorption with a prolonged duration of action.
Insulin detemir is a long-acting recombinant human insulin analog. It binds to insulin receptors, activating tyrosine kinase signaling, which promotes cellular glucose uptake, inhibits hepatic gluconeogenesis, and suppresses lipolysis and proteolysis.
Subcutaneous injection: 0.2 units/kg once daily or twice daily; usual total daily dose 0.5-1.0 units/kg. Adjust based on blood glucose levels.
0.2 units/kg subcutaneously once daily in the evening or twice daily (morning and evening) when used as basal insulin; titrate to target fasting glucose. For insulin-naive patients with type 2 diabetes, start at 10 units once daily in the evening. Dose adjustment of 1-4 units per day based on blood glucose monitoring.
None Documented
None Documented
Terminal elimination half-life: 13–18 hours (up to 24 hours with large doses); reflects prolonged absorption from subcutaneous depot due to dihexyl-deamination modification.
Terminal elimination half-life is 13–14 hours after subcutaneous administration, providing a flat, protracted pharmacokinetic profile suitable for once-daily dosing.
Renal: minimal, as insulin is extensively reabsorbed and degraded in the proximal tubule; hepatic metabolism: via receptor-mediated endocytosis and degradation by insulin-degrading enzyme; biliary/fecal: negligible.
Hepatic metabolism (deamidation at B30 and deacetylation at B29) and subsequent renal excretion; ~30% of dose excreted unchanged in urine.
Category C
Category C
Antidiabetic (Long-Acting Insulin)
Antidiabetic (Long-Acting Insulin)